Trial Search Results

A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects

This study will determine how morbid obesity affects the distribution and metabolism of the drug propofol. The investigators hypothesize that propofol will be distributed and metabolized differently in morbidly obese subjects as compared to normal weight subjects.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: propofol

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - adult age (ages 18-70)

   - body mass index greater than 40 or between 20-25

   - American Society of Anesthesiologists Class I, II, or III

   - undergoing elective surgical procedure requiring general anesthesia

Exclusion Criteria:

   - evidence of cardiovascular or pulmonary disease

   - kidney or liver dysfunction

   - drug allergy to propofol

   - history of difficult airway

   - on prescribed or over the counter anxiolytics, antipsychotics, or sleeping aids

   - unable to speak or understand English

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jerry Ingrande, M.D., M.S.
650-723-7377
Not Recruiting